Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Werewolf Therapeutics, a biopharmaceutical company focused on cancer treatment, announced that Randi Isaacs, M.D., its Chief Medical Officer, will present at the SVB Securities Global Biopharma Conference. The virtual presentation is scheduled for February 16, 2023, at 8:40 AM ET, during the conference which runs from February 14-16. This event highlights the company's innovative PREDATOR™ platform, designed to stimulate the immune system while minimizing peripheral activity. Werewolf's leading candidates, WTX-124 and WTX-330, are conditionally activated molecules aimed at treating various solid tumors. A link to the live webcast and archived presentation will be available following the event.

WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will present virtually at 8:40AM ET on February 16^th at the SVB Securities Global Biopharma Conference, taking place February 14^th-16^th, 2023.

A link to the live webcast for the conference will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the presentation.

About Werewolf Therapeutics:

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.

Investor Contact:
Josh Rappaport Stern IR
212.362.1200
Josh.Rappaport@sternir.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com

Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com

FAQ

What is the date of Randi Isaacs' presentation at the SVB Securities Global Biopharma Conference?

Randi Isaacs will present on February 16, 2023, at 8:40 AM ET.

Where can I watch the Werewolf Therapeutics presentation?

The presentation can be viewed via a live webcast available at https://investors.werewolftx.com/news-and-events/events.

What is the purpose of Werewolf Therapeutics' PREDATOR™ platform?

The PREDATOR™ platform is designed to stimulate the immune system specifically for cancer treatment while reducing activity in peripheral tissues.

What are the names of Werewolf Therapeutics' leading product candidates?

The leading candidates are WTX-124 and WTX-330, aimed at treating solid tumors.

How long will the archived presentation be available?

The archived replay of the presentation will be available for approximately 90 days.